Literature DB >> 8520509

Regulation of interleukin 6 in multiple myeloma and bone marrow stromal cells.

D Chauhan1, H Uchiyama, M Urashima, K Yamamoto, K C Anderson.   

Abstract

We and others have shown that some freshly isolated multiple myeloma (MM) cells and derived cell lines express interleukin 6 (IL-6) receptors and proliferate in vitro in response to IL-6; a subset of MM cells also expresses IL-6 mRNA, is intracytoplasmic IL-6 positive and secretes IL-6. We have shown that MM cells express the cell surface adhesion molecules CD29/CDw49d(VLA-4), CD18/CD11a(LFA-1) and CD44, and may localize to marrow via specific adherence to both extracellular matrix proteins and to bone marrow stromal cells (BMSCs). MM cell adhesion triggers IL-6 secretion by normal and MM BMSCs and related IL-6-mediated tumor cell growth. Our attempts to block MM cell adhesion to BMSC-induced IL-6 secretion by using antibodies to CD29/CDw49d, CD18/11a, and/or CD44 demonstrated minimal effects, suggesting that another ligand-receptor interaction triggers IL-6 secretion when MM cells and BMSCs are juxtaposed. Both MM cells and BMSCs express CD40. Triggering of MM cells and BMSCs via CD40 upregulates IL-6 secretion in both MM cells and MM-derived cell lines, as well as BMSCs and BMSC lines, suggesting the possibility of both autocrine and paracrine MM cell growth triggered via CD40. Finally, experiments using the LP 101 BMSC line transiently transfected with IL-6 promoter fragments linked to chloramphenicol acetyltransferase reporter gene demonstrate that adhesion of MM cells induces IL-6 gene transcription in BMSCs, which is conferred via the NF-kappa B binding motif.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8520509

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  11 in total

Review 1.  Pathogenesis beyond the cancer clone(s) in multiple myeloma.

Authors:  Giada Bianchi; Nikhil C Munshi
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

2.  Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells.

Authors:  Laurence Catley; Ellen Weisberg; Tanyel Kiziltepe; Yu-Tzu Tai; Teru Hideshima; Paola Neri; Pierfrancesco Tassone; Peter Atadja; Dharminder Chauhan; Nikhil C Munshi; Kenneth C Anderson
Journal:  Blood       Date:  2006-05-25       Impact factor: 22.113

3.  Caffeic acid phenethyl ester exerts apoptotic and oxidative stress on human multiple myeloma cells.

Authors:  Elizabeth Hernandez Marin; Hana Paek; Mei Li; Yesung Ban; Marie Katie Karaga; Rangaiah Shashidharamurthy; Xinyu Wang
Journal:  Invest New Drugs       Date:  2018-11-22       Impact factor: 3.850

Review 4.  New frontiers in the treatment of multiple myeloma.

Authors:  Janice Jin Hwang; Irene M Ghobrial; Kenneth C Anderson
Journal:  ScientificWorldJournal       Date:  2006-12-06

Review 5.  Novel treatment approaches for patients with relapsed and refractory multiple myeloma.

Authors:  Rajni Sinha; Sagar Lonial
Journal:  Curr Treat Options Oncol       Date:  2006-05

6.  Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias.

Authors:  Constantine S Mitsiades; Cecile Rouleau; Cinara Echart; Krishna Menon; Beverly Teicher; Maria Distaso; Antonio Palumbo; Mario Boccadoro; Kenneth C Anderson; Massimo Iacobelli; Paul G Richardson
Journal:  Clin Cancer Res       Date:  2009-02-15       Impact factor: 12.531

7.  HSP70 inhibition reverses cell adhesion mediated and acquired drug resistance in multiple myeloma.

Authors:  Ramadevi Nimmanapalli; Elvira Gerbino; William S Dalton; Varsha Gandhi; Melissa Alsina
Journal:  Br J Haematol       Date:  2008-05-22       Impact factor: 6.998

8.  Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation.

Authors:  Kenneth H Shain; Danielle N Yarde; Mark B Meads; Mei Huang; Richard Jove; Lori A Hazlehurst; William S Dalton
Journal:  Cancer Res       Date:  2009-01-20       Impact factor: 12.701

Review 9.  Targeting the UPS as therapy in multiple myeloma.

Authors:  Dharminder Chauhan; Giada Bianchi; Kenneth C Anderson
Journal:  BMC Biochem       Date:  2008-10-21       Impact factor: 4.059

Review 10.  Novel agents in the treatment of multiple myeloma: a review about the future.

Authors:  Leonard Naymagon; Maher Abdul-Hay
Journal:  J Hematol Oncol       Date:  2016-06-30       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.